Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Docta Complutense
Publication Artículo científico (JournalArticle)

Synergistic Effect of a Flavonoid-Rich Cocoa–Carob Blend and Metformin in Preserving Pancreatic Beta Cells in Zucker Diabetic Fatty Rats

  • Gallardo Villanueva, Paula
  • Fernández Marcelo, Tamara
  • Villamayor, Laura
  • Valverde, Ángela M.
  • Ramos, Sonia
  • Fernández Millán, Elisa
  • Martín, María Ángeles
The loss of functional beta-cell mass in diabetes is directly linked to the development of diabetic complications. Although dietary flavonoids have demonstrated antidiabetic properties, their potential effects on pancreatic beta-cell preservation and their synergistic benefits with antidiabetic drugs remain underexplored. We have developed a potential functional food enriched in flavonoids by combining cocoa powder and carob flour (CCB), which has shown antidiabetic effects. Here, we investigated the ability of the CCB, alone or in combination with metformin, to preserve pancreatic beta cells in an established diabetic context and their potential synergistic effect. Zucker diabetic fatty rats (ZDF) were fed a CCB-rich diet or a control diet, with or without metformin, for 12 weeks. Markers of pancreatic oxidative stress and inflammation, as well as relative beta-cell mass and beta-cell apoptosis, were analyzed. Results demonstrated that CCB feeding counteracted pancreatic oxidative stress by enhancing the antioxidant defense and reducing reactive oxygen species. Moreover, the CCB suppressed islet inflammation by preventing macrophage infiltration into islets and overproduction of pro-inflammatory cytokines, along with the inactivation of nuclear factor kappa B (NFκB). As a result, the CCB supplementation prevented beta-cell apoptosis and the loss of beta cells in ZDF diabetic animals. The observed additive effect when combining the CCB with metformin underscores its potential as an adjuvant therapy to delay the progression of type 2 diabetes.
Repisalud
Publication Artículo científico (JournalArticle)

The dual GLP-1/glucagon receptor agonist G49 mimics bariatric surgery effects by inducing metabolic rewiring and inter-organ crosstalk.

  • Valdecantos, M Pilar
  • Ruiz, Laura
  • Folgueira, Cintia
  • Rada, Patricia
  • Gomez-Santos, Beatriz
  • Solas, Maite
  • Hitos, Ana B
  • Field, Joss
  • Francisco, Vera
  • Escalona-Garrido, Carmen
  • Zagmutt, Sebastián
  • Calderon-Dominguez, María
  • Mera, Paula
  • Garcia-Martinez, Irma
  • Maymó-Masip, Elsa
  • Grajales, Diana
  • Alen, Rosa
  • Mora, Alfonso
  • Sáinz, Neira
  • Vides-Urrestarazu, Irene
  • Vilarrasa, Nuria
  • Arbones-Mainar, José M
  • Zaragoza, Carlos
  • Moreno-Aliaga, María J
  • Aspichueta, Patricia
  • Fernández-Veledo, Sonia
  • Vendrell, Joan
  • Serra, Dolors
  • Herrero, Laura
  • Schreiber, Renate
  • Zechner, Rudolf
  • Sabio, Guadalupe
  • Hornigold, David
  • Rondinone, Cristina M
  • Jermutus, Lutz
  • Grimsby, Joseph
  • Valverde, Ángela M
Bariatric surgery is effective for the treatment and remission of obesity and type 2 diabetes, but pharmacological approaches which exert similar metabolic adaptations are needed to avoid post-surgical complications. Here we show how G49, an oxyntomodulin (OXM) analog and dual glucagon/glucagon-like peptide-1 receptor (GCGR/GLP-1R) agonist, triggers an inter-organ crosstalk between adipose tissue, pancreas, and liver which is initiated by a rapid release of free fatty acids (FFAs) by white adipose tissue (WAT) in a GCGR-dependent manner. This interactome leads to elevations in adiponectin and fibroblast growth factor 21 (FGF21), causing WAT beiging, brown adipose tissue (BAT) activation, increased energy expenditure (EE) and weight loss. Elevation of OXM, under basal and postprandial conditions, and similar metabolic adaptations after G49 treatment were found in plasma from patients with obesity early after metabolic bariatric surgery. These results identify G49 as a potential pharmacological alternative sharing with bariatric surgery hormonal and metabolic pathways.
Repisalud
Publication Artículo científico (JournalArticle)

Protein kinase D2 modulates hepatic insulin sensitivity in male mice.

  • Rada, Patricia
  • Carceller-López, Elena
  • Hitos, Ana B
  • Gómez-Santos, Beatriz
  • Fernández-Hernández, Constanza
  • Rey, Esther
  • Pose-Utrilla, Julia
  • García-Monzón, Carmelo
  • González-Rodríguez, Águeda
  • Sabio, Guadalupe
  • García, Antonia
  • Aspichueta, Patricia
  • Iglesias, Teresa
  • Valverde, Ángela M
Protein kinase D (PKD) family is emerging as relevant regulator of metabolic homeostasis. However, the precise role of PKD2 in modulating hepatic insulin signaling has not been fully elucidated and it is the aim of this study. PKD inhibition was analyzed for insulin signaling in mouse and human hepatocytes. PKD2 was overexpressed in Huh7 hepatocytes and mouse liver, and insulin responses were evaluated. Mice with hepatocyte-specific PKD2 depletion (PKD2) and PKD2 mice were fed a chow (CHD) or high fat diet (HFD) and glucose homeostasis and lipid metabolism were investigated. PKD2 silencing enhanced insulin signaling in hepatocytes, an effect also found in primary hepatocytes from PKD2 mice. Conversely, a constitutively active PKD2 mutant reduced insulin-stimulated AKT phosphorylation. A more in-depth analysis revealed reduced IRS1 serine phosphorylation under basal conditions and increased IRS1 tyrosine phosphorylation in PKD2 primary hepatocytes upon insulin stimulation and, importantly PKD co-immunoprecipitates with IRS1. In vivo constitutively active PKD2 overexpression resulted in a moderate impairment of glucose homeostasis and reduced insulin signaling in the liver. On the contrary, HFD-fed PKD2 male mice displayed improved glucose and pyruvate tolerance, as well as higher peripheral insulin tolerance and enhanced hepatic insulin signaling compared to control PKD2 mice. Despite of a remodeling of hepatic lipid metabolism in HFD-fed PKD2 mice, similar steatosis grade was found in both genotypes. Results herein have unveiled an unknown role of PKD2 in the control of insulin signaling in the liver at the level of IRS1 and point PKD2 as a therapeutic target for hepatic insulin resistance.